Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 3/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 12/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.46 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20363366 | 0.93 | OPRK1 (0.49) | RENOPRK1PSMB5PSMB8CTSS | |
| SCHEMBL13290906 | 0.92 | OPRK1 (0.50) | RENOPRK1 | |
| SCHEMBL11931215 | 0.91 | OPRK1 (0.49) | RENOPRK1 | |
| SCHEMBL25729851 | 0.91 | OPRK1 (0.49) | RENOPRK1 | |
| SCHEMBL22957130 | 0.90 | REN (0.51) | RENOPRK1PSMB5PSMB8CTSS | |
| SCHEMBL13290898 | 0.90 | OPRK1 (0.48) | RENOPRK1 | |
| SCHEMBL11927495 | 0.89 | OPRK1 (0.55) | RENOPRK1PSMB5PSMB8CTSS | |
| SCHEMBL10316461 | 0.88 | OPRK1 (0.47) | OPRK1 | |
| SCHEMBL11927497 | 0.88 | OPRK1 (0.47) | RENOPRK1 | |
| SCHEMBL22957113 | 0.86 | TMPRSS11D (0.52) | OPRK1PSMB5PSMB8CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | CARA THERAPEUTICS INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | CARA THERAPEUTICS INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2022-04-28 | — | — | US | disclosed |
| US-11083726-B2 | Methods and compositions for treating vasomotor symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2021-08-10 | — | — | US | disclosed |
| US-11033629-B2 | Oral formulations of kappa opioid receptor agonists | CARA THERAPEUTICS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210030745-A9 | Methods and Compositions for Treating Vasomotor Symptoms | ACER THERAPEUTICS INC. | 2021-02-04 | — | — | US | disclosed |
| US-20200085961-A1 | Oral Formulations of Kappa Opioid Receptor Agonists | CARA THERAPEUTICS, INC. | 2020-03-19 | — | — | US | disclosed |
| US-20190255037-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2019-08-22 | — | — | US | disclosed |
| US-10017536-B2 | Synthetic peptide amides and dimers thereof | CARA THERAPEUTICS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170231979-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2017-08-17 | — | — | US | disclosed |
| US-7842662-B2 | of kappa opioid receptor and agonists thereof, exhibit low P450 CYP inhibition and low penetration into the brain; visceral pain, neuropathic pain, hyperalgesia, irritabile bowel syndrome, ocular and otic inflammation, pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma | CARA THERAPEUTICS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842662-B2 | of kappa opioid receptor and agonists thereof, exhibit low P450 CYP inhibition and low penetration into the brain; visceral pain, neuropathic pain, hyperalgesia, irritabile bowel syndrome, ocular and otic inflammation, pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma | CARA THERAPEUTICS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7713937-B2 | Synthetic peptide amides and dimeric forms thereof | CARA THERAPEUTICS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713937-B2 | Synthetic peptide amides and dimeric forms thereof | CARA THERAPEUTICS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20090264373-A1 | of kappa opioid receptor and agonists thereof, exhibit low P450 CYP inhibition and low penetration into the brain; visceral pain, neuropathic pain, hyperalgesia, irritabile bowel syndrome, ocular and otic inflammation, pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma | CARA THERAPEUTICS, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090264373-A1 | of kappa opioid receptor and agonists thereof, exhibit low P450 CYP inhibition and low penetration into the brain; visceral pain, neuropathic pain, hyperalgesia, irritabile bowel syndrome, ocular and otic inflammation, pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma | CARA THERAPEUTICS, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090156508-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156508-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210030745-A9 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | REN 393/4885OPRK1 554/4885PSMB5 4100/4885 |
| US-20190255037-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | REN 393/4885OPRK1 554/4885PSMB5 4100/4885 |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | OPRK1, OPRD1, OPRM1 | REN 2078/4885OPRK1 1/4885PSMB5 1040/4885 |
| US-11083726-B2 | Methods and compositions for treating vasomotor symptoms | VASP, PDE3A, PDE2A | REN 393/4885OPRK1 554/4885PSMB5 4100/4885 |
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | OPRK1, OPRL1, OGFR | REN 3048/4885OPRK1 1/4885PSMB5 2240/4885 |
| US-20090156508-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | OPRK1, OPRM1, OPRL1 | REN 1921/4885OPRK1 1/4885PSMB5 999/4885 |
| US-20090264373-A1 | of kappa opioid receptor and agonists thereof, exhibit low P450 CYP inhibition and low penetration into the brain; visceral pain, neuropathic pain, hyperalgesia, irritabile bowel syndrome, ocular and otic inflammation, pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma | OPRK1, OPRD1, OGFR | REN 783/4885OPRK1 1/4885PSMB5 2663/4885 |
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | REN 393/4885OPRK1 554/4885PSMB5 4100/4885 |
| US-20170231979-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | REN 393/4885OPRK1 554/4885PSMB5 4100/4885 |
| US-11033629-B2 | Oral formulations of kappa opioid receptor agonists | OPRK1, OPRL1, OGFR | REN 3048/4885OPRK1 1/4885PSMB5 2240/4885 |
| US-10017536-B2 | Synthetic peptide amides and dimers thereof | OPRK1, OPRL1, OPRM1 | REN 1954/4885OPRK1 1/4885PSMB5 992/4885 |
| US-20200085961-A1 | Oral Formulations of Kappa Opioid Receptor Agonists | OPRK1, OPRL1, OGFR | REN 3048/4885OPRK1 1/4885PSMB5 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.